Providing the First Mechanistic Basis for Halting Neurodegenerative Disease: Targeting c-Abl to Reverse Parkinson’s Disease

Time: 9:30 am
day: Day Two


  • Discussing the discovery of the biochemical process underlying the initiation and progression of Parkinson’s disease to rationalize c-Abl targeting
  • Optimizing drug design of c-Abl inhibitor IkT-148009 to halt Parkinson’s disease and restore functional loss to effectively reverse Parkinson’s disease
  • Reflecting on preclinical data to supercharge phase 1 trials for IkT-148009